These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 36518802)
1. The expression of androgen receptor in triple-negative breast cancer and the effect of a traditional Chinese medicine formula on disease-free survival. Yu L; Yu Q; Xu C; Wang M; Song J; Gao X Gland Surg; 2022 Nov; 11(11):1772-1783. PubMed ID: 36518802 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy. Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis. Xu M; Yuan Y; Yan P; Jiang J; Ma P; Niu X; Ma S; Cai H; Yang K Clin Breast Cancer; 2020 Aug; 20(4):e385-e396. PubMed ID: 32139270 [TBL] [Abstract][Full Text] [Related]
5. Association between androgen receptor status and prognosis in triple negative breast cancer. Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308 [TBL] [Abstract][Full Text] [Related]
8. Clinical observation on the effect of Chinese medicine-"TCM formula" intervention on recurrence and metastasis of triple negative breast cancer. Wang Y; Li JW; Qin YN; Sun CP; Chen JJ; Ruan YY; Chen LX; Liu S; Liu GY Complement Ther Med; 2020 Aug; 52():102456. PubMed ID: 32951717 [TBL] [Abstract][Full Text] [Related]
9. Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-Analysis. Kim Y; Jae E; Yoon M J Breast Cancer; 2015 Jun; 18(2):134-42. PubMed ID: 26155289 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response. Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539 [TBL] [Abstract][Full Text] [Related]
11. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer. Riaz N; Idress R; Habib S; Lalani EN Front Oncol; 2020; 10():1083. PubMed ID: 32850312 [No Abstract] [Full Text] [Related]
12. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer. Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566 [TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Choi JE; Kang SH; Lee SJ; Bae YK Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503 [TBL] [Abstract][Full Text] [Related]
14. Incidence and Prognostic Significance of Androgen Receptors (AR) in Indian Triple-Negative Breast Cancer (TNBC). Mishra A; Mishra SK; Sharanappa V; Krishnani N; Kumari N; Agarwal G Indian J Surg Oncol; 2024 Jun; 15(2):250-257. PubMed ID: 38741650 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. He J; Peng R; Yuan Z; Wang S; Peng J; Lin G; Jiang X; Qin T Med Oncol; 2012 Jun; 29(2):406-10. PubMed ID: 21264529 [TBL] [Abstract][Full Text] [Related]
16. [Safety of breast-conserving treatment for triple-negative breast cancer]. Wang L; Ouyang T; Wang T; Xie Y; Fan Z; Fan T; Li J Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):947-52. PubMed ID: 26850668 [TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Pistelli M; Caramanti M; Biscotti T; Santinelli A; Pagliacci A; De Lisa M; Ballatore Z; Ridolfi F; Maccaroni E; Bracci R; Berardi R; Battelli N; Cascinu S Cancers (Basel); 2014 Jun; 6(3):1351-62. PubMed ID: 24978437 [TBL] [Abstract][Full Text] [Related]
18. Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer. Asano Y; Kashiwagi S; Goto W; Tanaka S; Morisaki T; Takashima T; Noda S; Onoda N; Ohsawa M; Hirakawa K; Ohira M Cancers (Basel); 2017 Jan; 9(1):. PubMed ID: 28067809 [TBL] [Abstract][Full Text] [Related]
19. Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer. Prabhu JS; Korlimarla A; Rajarajan S; Alexander A; Anupama C; Ramesh R; Srinath B; Sridhar TS Cancer Res; 2021 Feb; 81(4 Suppl):. PubMed ID: 34421401 [TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Mantiero M; Tasca G; Cumerlato E; Giorgi CA; Giarratano T; Faggioni G; Falci C; Vernaci G; Menichetti A; Mioranza E; Di Liso E; Frezzini S; Saibene T; Orvieto E; Guarneri V Front Oncol; 2019; 9():452. PubMed ID: 31245286 [No Abstract] [Full Text] [Related] [Next] [New Search]